Influence of ECMO on concentration-time courses of certain antibiotics in patients with acute lung failure

Influence of ECMO on concentration-time courses of certain antibiotics in patients with acute lung failure - ECMO-PHANT

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00005694

Enrollment

Registered

2014-02-04

Start date

2014-03-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

J80

Interventions

Group 1: Patients with ARDS and indication for ECMO and indication for antibiotic therapy with Cefotaxime or Meropenem. We analyse the time course of its serum concentration before the start of ECMO

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: patients with 1. ARDS with indication for ECMO or ECCO2-R (i.e. p/F 79 and individually optimised PEEP and/or pH < 7,30) and 2. indication for Cefotaxime or Meropenem and 3. informed consent

Exclusion criteria

Exclusion criteria: - emergency ECMO 20 % difference in norepinephrine dose during the last hours)

Design outcomes

Primary

Measure	Time frame
concentration - time - course of Cefotaxime and Meropenem without and with ECMO (extracorporeal membrane oxygenation)	—

Countries

Germany

Contacts

Public ContactSigrun Friesecke

Universitätsmedizin GreifswaldKlinik für Innere Medizin B

sigrun.friesecke@uni-greifswald.de+49 (03834) 8680668

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026